Cargando…

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience

BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohan, Sandy S., Sicklick, Jason K., Kato, Shumei, Okamura, Ryosuke, Miller, Vincent A., Leyland‐Jones, Brian, Lippman, Scott M., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648352/
https://www.ncbi.nlm.nih.gov/pubmed/32949172
http://dx.doi.org/10.1002/onco.13532
_version_ 1783607095550017536
author Bohan, Sandy S.
Sicklick, Jason K.
Kato, Shumei
Okamura, Ryosuke
Miller, Vincent A.
Leyland‐Jones, Brian
Lippman, Scott M.
Kurzrock, Razelle
author_facet Bohan, Sandy S.
Sicklick, Jason K.
Kato, Shumei
Okamura, Ryosuke
Miller, Vincent A.
Leyland‐Jones, Brian
Lippman, Scott M.
Kurzrock, Razelle
author_sort Bohan, Sandy S.
collection PubMed
description BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicine trial. MATERIALS AND METHODS: Study participants were 190 adult patients who consented to the I‐PREDICT (Investigation of molecular Profile‐Related Evidence Determining Individualized Cancer Therapy) trial. Patients had metastatic and/or unresectable incurable malignancies. Patients who were not evaluable were analyzed. RESULTS: Of consented patients, 44% were not evaluable. Men were twice as likely to be not evaluable as women. Prominently, 45% of patients who were not evaluable dropped off because of death, hospice referral, or decline in organ function. CONCLUSION: Health deterioration of consented patients is a significant barrier to being evaluable on the I‐PREDICT trial. These data suggest that patients are enrolled on precision oncology trials too late in their disease course or with excessive disease burden.
format Online
Article
Text
id pubmed-7648352
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-76483522020-11-16 Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience Bohan, Sandy S. Sicklick, Jason K. Kato, Shumei Okamura, Ryosuke Miller, Vincent A. Leyland‐Jones, Brian Lippman, Scott M. Kurzrock, Razelle Oncologist Brief Communications BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicine trial. MATERIALS AND METHODS: Study participants were 190 adult patients who consented to the I‐PREDICT (Investigation of molecular Profile‐Related Evidence Determining Individualized Cancer Therapy) trial. Patients had metastatic and/or unresectable incurable malignancies. Patients who were not evaluable were analyzed. RESULTS: Of consented patients, 44% were not evaluable. Men were twice as likely to be not evaluable as women. Prominently, 45% of patients who were not evaluable dropped off because of death, hospice referral, or decline in organ function. CONCLUSION: Health deterioration of consented patients is a significant barrier to being evaluable on the I‐PREDICT trial. These data suggest that patients are enrolled on precision oncology trials too late in their disease course or with excessive disease burden. John Wiley & Sons, Inc. 2020-10-02 2020-11 /pmc/articles/PMC7648352/ /pubmed/32949172 http://dx.doi.org/10.1002/onco.13532 Text en © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Bohan, Sandy S.
Sicklick, Jason K.
Kato, Shumei
Okamura, Ryosuke
Miller, Vincent A.
Leyland‐Jones, Brian
Lippman, Scott M.
Kurzrock, Razelle
Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
title Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
title_full Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
title_fullStr Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
title_full_unstemmed Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
title_short Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
title_sort attrition of patients on a precision oncology trial: analysis of the i‐predict experience
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648352/
https://www.ncbi.nlm.nih.gov/pubmed/32949172
http://dx.doi.org/10.1002/onco.13532
work_keys_str_mv AT bohansandys attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT sicklickjasonk attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT katoshumei attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT okamuraryosuke attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT millervincenta attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT leylandjonesbrian attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT lippmanscottm attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience
AT kurzrockrazelle attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience